Guide

The approved pills changed the maths

Two oral GLP-1s were approved either side of the new year, both starting at $149 a month. That undercuts a large part of the compounded market.

Updated 2026-09-18 · Prices verified independently

Why you can trust this: we take payment from one company on this page — Coreage Rx — when a reader signs up through our link. It does not change the prices we print or the rubric we score against, both of which are published in full on how we rate. Read our full disclosure.

The whole argument for compounded GLP-1s was price. Two FDA-approved pills have now largely taken that argument away, and a lot of review sites have not caught up.

Both start at $149 a month self-pay. That is more than the cheapest compounded programmes — Ozari Health is $86 and Trimi is $125 — but it is less than the majority of what we track, and it buys a product the FDA has actually reviewed.

Wegovy pill (oral semaglutide)

Approved late December 2025, launched in the US on 5 January 2026. The first oral GLP-1 approved for weight management — the same active ingredient as the Wegovy injection, taken as a daily tablet.

Self-pay from $149/month for the 1.5 mg starting dose. The 4 mg dose was offered at $149/month through 15 April 2026 and $199/month after, with the highest doses around $299/month.

Available through LillyDirect-style manufacturer channels and telehealth partners including Ro, GoodRx Care Direct and Walgreens.

Foundayo (orforglipron)

FDA approved 1 April 2026. The first oral small-molecule, non-peptide GLP-1 receptor agonist approved for weight management. Unlike oral semaglutide it is not a peptide, so it has no food-and-water timing restrictions of the same kind.

Self-pay from $149/month for the lowest 0.8 mg dose, about $199/month at 2.5 mg, and roughly $299-$349/month at higher doses.

Self-pay through LillyDirect, with telehealth partners including Ro.

How they compare with what we normally cover

Option	From	Form	FDA-approved?
Wegovy pill (oral semaglutide)	$149/mo	Daily tablet	Yes
Foundayo (orforglipron)	$149/mo	Daily tablet	Yes
Cheapest compounded semaglutide (Ozari Health)	$86/mo	Weekly injection	No
Cheapest compounded tirzepatide (Trimi)	$125/mo	Weekly injection	No
Typical compounded programme	$189–$449/mo	Weekly injection	No
Wegovy injection, self-pay	$199 then $349/mo	Weekly injection	Yes

What this does not mean

A pill is not automatically better than an injection. Oral semaglutide has strict instructions about taking it on an empty stomach with a small sip of water and waiting before eating — get that wrong and it underperforms. And the trial weight-loss figures for injectable tirzepatide remain the highest of any of these options.

Who should actually consider switching

Anyone paying more than about $200 a month for a compounded injection. You are now paying a premium for a non-approved product, which is a strange place to be.
Anyone who never wanted to inject. This is the obvious one — a genuine approved alternative now exists at a sane price.
Anyone uneasy about the compounding rules. The 2026 regulatory direction is not friendly to compounded GLP-1s; see is compounded still legal.
Medicare beneficiaries. From July 2026 you may be able to get an approved GLP-1 for $50 a month — see the Medicare programme.

Who probably should not

If you are already on Trimi or Ozari Health at under $130 a month, tolerating it well and getting results, the approved pills cost more. That is a real reason to stay put. The comparison changes if your programme raises prices or your dose pushes you into a higher tier.

Whichever direction you are considering, it is a conversation with a prescriber rather than a purchase decision. Both drugs have contraindications, and switching between them is not simply swapping one box for another.